Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
$7.53
-$1.70(-8.19%)
At close: 4:00 PM EST
$7.53
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$215.10M
Enterprise Value$54.86M
Total Cash (Recent Filing)$180.36M
Total Debt (Recent Filing)$21.86M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 02, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding28,414,280
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.90
Price to Sales (P/S)3.31
P/FCF Ratio-7.59
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit0.62
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$25.17Price Target Upside234.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company maintains a cash runway extending into 2028 after cost-control measures, reducing the likelihood of near-term financing needs while development continues.
Pipeline ValuationAnalyst views the stock as materially underpriced because the market is valuing the pipeline as having little to no chance of success despite programs with significant commercial potential.
Platform ValidationPositive ARC-810 readouts indicate the company's purified mRNA can reach target cells and generate functional enzymes, supporting the platform's therapeutic potential.
Bears Say
Clinical Efficacy RiskThe absence of a clinically meaningful FEV1 improvement in the Phase II CF study leaves the core efficacy link unproven and creates a key inflection risk for future approvals.
Partner SetbackPartner CSL's decision to not submit a U.S. BLA for KOSTAIVE removes an approval milestone and weakens the company's vaccine development pathway.
Regulatory UncertaintyUncertainty about regulatory expectations and cautious interpretation of early ARCT-032 results has contributed to investor concern and valuation pressure.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $215.10M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 20 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.899 by $0.409.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,414,280 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.899. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.17 (234.26% Upside)
$25.17 (234.26% Upside)
Hedge Fund Trend
Decreased
By 556.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-27.43%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and strategic partnerships, but was overshadowed by significant financial challenges, including revenue decline and increased net loss. The indefinite delay in the Costave BLA filing represents a major hurdle for the company's commercial prospects in the US market.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$25.17
▲(234.26% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.05% Insiders
29.28% Mutual Funds
0.16% Other Institutional Investors
42.02% Public Companies and Individual Investors